Roivant Sciences Ltd. $ROIV Shares Newly Purchased by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd acquired a new position in Roivant Sciences Ltd. (NASDAQ:ROIV) in the third quarter, Holdings Channel.com reports. The firm acquired 61,728 shares of the company’s stock, valued at approximately $2,257,000.

Other institutional investors have also recently modified their holdings of the company. Waverly Advisors LLC raised its holdings in shares of Roivant Sciences by 2.3% during the 2nd quarter. Waverly Advisors LLC now owns 12,869 shares of the company’s stock valued at $455,000 after buying an additional 291 shares in the last quarter. Fifth Third Bancorp lifted its position in Roivant Sciences by 8.7% in the 1st quarter. Fifth Third Bancorp now owns 4,686 shares of the company’s stock worth $130,000 after buying an additional 376 shares during the last quarter. Bessemer Group Inc. boosted its stake in Roivant Sciences by 21.8% in the first quarter. Bessemer Group Inc. now owns 2,465 shares of the company’s stock worth $69,000 after buying an additional 441 shares in the last quarter. Fifth Third Wealth Advisors LLC boosted its stake in Roivant Sciences by 4.6% in the first quarter. Fifth Third Wealth Advisors LLC now owns 10,166 shares of the company’s stock worth $282,000 after buying an additional 445 shares in the last quarter. Finally, Versant Capital Management Inc boosted its stake in Roivant Sciences by 13.9% in the second quarter. Versant Capital Management Inc now owns 3,995 shares of the company’s stock worth $141,000 after buying an additional 487 shares in the last quarter. 64.76% of the stock is currently owned by institutional investors.

Roivant Sciences Trading Up 1.8%

Roivant Sciences stock opened at $37.45 on Friday. Roivant Sciences Ltd. has a 1-year low of $17.89 and a 1-year high of $42.50. The firm has a 50-day moving average of $36.61 and a 200-day moving average of $33.32.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.04. Roivant Sciences had a negative return on equity of 22.94% and a negative net margin of 3,534.96%. The company had revenue of $1.44 million for the quarter, compared to the consensus estimate of $2.06 million. On average, analysts expect that Roivant Sciences Ltd. will post -2.00 earnings per share for the current year.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Brepocitinib met both Phase 3 primary endpoints. Roivant and Priovant reported that the CLARITY-1 and CLARITY-2 trials achieved their primary goals in non-infectious uveitis. The drug also delivered statistically significant and clinically meaningful improvements in key secondary measures, including sustained steroid-free disease control, reduced vascular leakage, resolution of macular edema and better patient-reported visual functioning. Roivant and Priovant announce positive brepocitinib Phase 3 results
• Positive Sentiment: The trial data could expand the drug’s commercial opportunity. Coverage highlighted brepocitinib’s ability to reduce reliance on steroids in inflammatory eye disease, while Roivant is expected to pursue a label expansion for Lisraya in uveitis. Positive commentary and analyst coverage contributed to the stock’s upward move. Roivant’s TYK2/JAK inhibitor reduces need for steroids
• Neutral Sentiment: Roivant will report fiscal second-quarter results on November 9, 2026. Investors will receive updated financial results and a business outlook, including any regulatory or commercialization plans related to brepocitinib. Roivant quarterly earnings announcement
• Negative Sentiment: CEO Eric Venker sold 200,000 shares worth approximately $7.0 million. The sale reduced his direct ownership by 12.5%, which may draw investor attention. However, it was executed under a pre-arranged Rule 10b5-1 trading plan, reducing its significance as a discretionary bearish signal. SEC insider transaction filing

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 24th. UBS Group set a $55.00 price target on shares of Roivant Sciences in a research report on Wednesday, September 9th. Wolfe Research cut Roivant Sciences from an “outperform” rating to a “peer perform” rating in a research note on Monday, October 12th. Stifel Nicolaus started coverage on Roivant Sciences in a research note on Wednesday, September 16th. They set a “buy” rating and a $51.00 price objective on the stock. Finally, Citigroup reiterated a “buy” rating on shares of Roivant Sciences in a report on Monday, October 12th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.64.

Insiders Place Their Bets

In other news, Director Melissa B. Epperly sold 17,750 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $36.10, for a total transaction of $640,775.00. Following the transaction, the director directly owned 14,954 shares of the company’s stock, valued at approximately $539,839.40. The trade was a 54.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Eric Venker sold 200,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 20th. The shares were sold at an average price of $35.11, for a total value of $7,022,000.00. Following the transaction, the chief executive officer owned 1,399,154 shares of the company’s stock, valued at approximately $49,124,296.94. This represents a 12.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,822,688 shares of company stock worth $65,848,636. 8.80% of the stock is currently owned by company insiders.

About Roivant Sciences

Roivant Sciences Ltd. (NASDAQ: ROIV) is a biopharmaceutical company focused on discovering, developing and commercializing medicines. The company organizes its activities through subsidiaries and partner companies, often referred to as “Vants,” which specialize in particular therapeutic areas and stages of drug development.

Roivant’s research and development activities have included immunology, dermatology, women’s health, rare diseases and other specialty-care fields. Its portfolio has included Vtama (tapinarof) cream, a nonsteroidal topical treatment approved in the United States for plaque psoriasis and atopic dermatitis.